[{"address1": "88 Sidney Street", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "617 649 8600", "website": "https://www.agios.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 383, "auditRisk": 6, "boardRisk": 3, "compensationRisk": 4, "shareHolderRightsRisk": 7, "overallRisk": 5, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 42.45, "open": 42.55, "dayLow": 42.47, "dayHigh": 45.3, "regularMarketPreviousClose": 42.45, "regularMarketOpen": 42.55, "regularMarketDayLow": 42.47, "regularMarketDayHigh": 45.3, "beta": 0.771, "forwardPE": -8.046264, "volume": 2705397, "regularMarketVolume": 2705397, "averageVolume": 806961, "averageVolume10days": 938290, "averageDailyVolume10Day": 938290, "bid": 44.87, "ask": 45.35, "bidSize": 400, "askSize": 1100, "marketCap": 2567275008, "fiftyTwoWeekLow": 19.8, "fiftyTwoWeekHigh": 49.06, "priceToSalesTrailing12Months": 87.31337, "fiftyDayAverage": 36.4978, "twoHundredDayAverage": 27.796, "currency": "USD", "enterpriseValue": 2037629568, "floatShares": 47374769, "sharesOutstanding": 56773000, "sharesShort": 6082711, "sharesShortPriorMonth": 6653774, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1071, "heldPercentInsiders": 0.01482, "heldPercentInstitutions": 1.11133, "shortRatio": 8.93, "shortPercentOfFloat": 0.1087, "impliedSharesOutstanding": 56773000, "bookValue": 13.108, "priceToBook": 3.4498017, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -352619008, "trailingEps": -6.31, "forwardEps": -5.62, "pegRatio": -0.46, "enterpriseToRevenue": 69.3, "enterpriseToEbitda": -5.268, "52WeekChange": 0.6461594, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AGIO", "underlyingSymbol": "AGIO", "shortName": "Agios Pharmaceuticals, Inc.", "longName": "Agios Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1374672600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "52f076ec-0de6-382e-b01b-3ddfa165dcb4", "messageBoardId": "finmb_46539787", "gmtOffSetMilliseconds": -14400000, "currentPrice": 45.22, "targetHighPrice": 61.0, "targetLowPrice": 49.0, "targetMeanPrice": 54.2, "targetMedianPrice": 53.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 597990976, "totalCashPerShare": 10.533, "ebitda": -386764992, "totalDebt": 68347000, "quickRatio": 11.635, "currentRatio": 12.838, "totalRevenue": 29403000, "debtToEquity": 9.187, "revenuePerShare": 0.526, "returnOnAssets": -0.24547, "returnOnEquity": -0.3961, "freeCashflow": -221808256, "operatingCashflow": -300745984, "revenueGrowth": 0.46, "operatingMargins": -11.243381, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]